Skip to Content
Search Menu

Nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma

The Phase 3 study CONFIRM presented at WCLC 2020 show that nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Pembrolizumab plus chemotherapy provided durable clinical benefit in patients with metastatic squamous NSCLC

/ Martin Reck
NSCLCWCLC20 Play the Video 8:48

Pembrolizumab with chemo-radiation therapy showed promising antitumor activity in unresectable, locally advanced, stage III NSCLC

/ Martin Reck
NSCLCWCLC20 Play the Video 7:17

WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

/ Roy S. Herbst
NSCLCWCLC20 Play the Video 2:25

WCLC2020: COVID-19 outcomes in patients with thoracic malignancies

/ Umit Tapan
COVID-19WCLC20 Play the Video 16:35

12 months data from KEYNOTE-799 confirm promising response rates with pembrolizumab in combination with chemo-radiation therapy for locally advanced NSCLC

/ BestPractice Nordic
NSCLCWCLC20

Promising results with neoadjuvant atezolizumab for stage IB-IIIB NSCLC

/ BestPractice Nordic
NSCLCWCLC20

WCLC2020: Pre-operative treatment with atezolizumab in untreated stage IB-IIIB resectable NSCLC

/ Jay M. Lee
NSCLCWCLC20 Play the Video 10:38

KEYNOTE-598 confirms current standard of care in metastatic 1L NSCLC patients with PD-L1 TPS ≥50%

/ BestPractice Nordic
NSCLCWCLC20

Post hoc analysis shows a clear correlation between high expression of PDL1 and efficacy of cemiplimab

/ BestPractice Nordic
WCLC20
Back to top